Table 4.
A comparison of the type of vaccine administered and recorded mortality in patients with a CVD, solid malignancy or CPD
| Vaccine type | Fully vaccinated with CVD | Mortality (CVD) | Fully vaccinated with a solid malignancy | Mortality (malignancy) | Fully vaccinated with a CPD | Mortality (CPD) |
| BNT162b2 | 7507 (63.58%) | 216 (2.88%) | 210 (60.34%) | 9 (4.28%) | 316 (85.50%) | 13 (4.95%) |
| CX-024414 | 823 (6.97%) | 26 (3.16%) | 38 (10.92%) | 3 (7.89%) | 53 (9.23%) | 1 (1.88%) |
| ChAdOx1-SARS-COV-2 | 586 (4.97%) | 76 (12.96%) | 17 (4.88%) | 3 (17.64%) | 27 (4.70%) | 3 (11.11%) |
| Ad26.COV2-S | 1706 (14.45%) | 81 (4.74%) | 55 (15.80%) | 2 (3.63%) | 121 (21.08%) | 6 (4.95%) |
| CX-024414+BNT162b2 | 251 (2.12%) | 2 (0.80%) | 7 (2.01%) | 0 | 13 (2.26%) | 0 |
| ChAdOx1-SARS-COV-2+BNT162b2 | 619 (5.25%) | 7 (1.13%) | 12 (3.45%) | 0 | 29 (5.05%) | 3 (10.34%) |
| ChAdOx1-SARS-COV-2+CX-024414 | 42 (0.35%) | 0 | 0 | 0 | 2 (0.35%) | 0 |
| ChAdOx1-SARS-COV-2+Ad26.COV2-S | 1 (0.008%) | 0 | 0 | 0 | 0 | 0 |
| Ad26.COV2-S+BNT162b2 | 222 (1.88%) | 2 (0.90%) | 8 (2.30%) | 0 | 10 (1.74%) | 0 |
| Ad26.COV2-S+CX-024414 | 48 (0.40%) | 0 | 1 (0.30%) | 0 | 3 (0.52%) | 0 |
| ChAdOx1-SARS-COV-2+BNT162b2+CX-024414 | 2 (0.016%) | 0 | 0 | 0 | 0 | 0 |
| ChAdOx1-SARS-COV-2+Ad26.COV2-S+CX-024414 | 1 (0.008%) | 0 | 0 | 0 | 0 | 0 |
| Total (vaccinated) | 11 808 | 410 (0.73%) | 348 | 17 (0.94%) | 574 | 26 (0.96%) |
| Total (non-vaccinated) | NA | 55 915 (99.27%) | NA | 1792 (99.06%) | NA | 2669 (99.04%) |
The total mortality rates of the unvaccinated cohorts were added for reference.
CPD, chronic pulmonary disease; CVD, cardiovascular disease; NA, not applicable.